The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).
Solwers Plc's Financial Statements Release 1 January-31 December 2025 (Unaudited) Solwers Plc Company Release March 5, 2026, at 08:30 a.m. EET Moderate Revenue Growth in 2025, Additional Focus on Prof ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results